Splicing DNA that had never met
In 1973, Stanley Cohen and Herbert Boyer showed that DNA from one organism could be spliced into the DNA of another and made to work there, creating a molecule that existed nowhere in nature: recombinant DNA. Their method used restriction enzymes, which cut DNA at specific sequences, to remove a gene of interest and insert it into a plasmid, a small circular loop of DNA that bacteria carry separately from their main genome. Once the modified plasmid was introduced into a bacterial cell through a process called transformation, the bacterium copied it along with its own DNA every time it divided, and, crucially, could be induced to read the foreign gene and produce the protein it coded for. The claim was not merely that DNA from different sources could be joined physically, but that a living cell could be made to treat foreign genetic instructions as its own.
Cut, insert, transform, express
The technique itself was, by molecular biology standards, straightforward once assembled: restriction enzymes to cut, a plasmid vector to carry, and bacterial transformation to deliver the foreign DNA into a cell that would then replicate it indefinitely. Cohen and Boyer combined tools that had each been developed separately in the preceding years, and Stanford filed a patent on the method in November 1974, naming both men as inventors, a patent eventually granted in December 1980. The demonstration that a bacterium could be induced to express a gene from an entirely different species, rather than merely carry it inertly, is what turned the technique from a laboratory curiosity into the foundation of an entire industry, since it meant bacteria could, in principle, be turned into factories for any protein whose gene could be identified and inserted.
From a 1973 demonstration to a licensed drug
The basic method has held up as the working foundation of genetic engineering for half a century, extended and refined but not overturned. Boyer’s own laboratory, together with Keiichi Itakura and Arthur Riggs at the City of Hope National Medical Center, used the technique in 1978 to produce human insulin from genetically modified bacteria, a result that Genentech, the company Boyer co-founded with Robert Swanson in 1976, turned into the first licensed drug made through recombinant DNA technology, later manufactured under licence by Eli Lilly. The same basic recipe, cut, insert, transform, express, has since been used to produce human growth hormone, blood-clotting factors and hepatitis B vaccine components, and a version of it, recombinant chymosin, is now used in roughly sixty per cent of hard cheese made in the United States, replacing an enzyme once extracted from calf stomachs.
A field pausing itself
What the 1973 experiment did not settle, and what its own practitioners recognised almost immediately, was whether the technique was safe to use freely. Scientists organised the Asilomar Conference in 1975, just two years after the original demonstration, specifically because inserting foreign genes into fast-replicating bacteria raised genuine, unresolved questions about what might happen if an engineered organism escaped a laboratory or behaved unpredictably. The result was a voluntary moratorium on the riskiest categories of experiment, self-imposed by the researchers themselves rather than required by any external regulator, which held until the National Institutes of Health established formal guidelines. That the field paused itself before any government required it to remains a distinctive feature of the story, and one that later commentators have pointed to as an unusually early example of scientists regulating a new capability before an incident forced the issue.
From slaughterhouses to bacterial factories
The practical consequence of the Cohen-Boyer technique was to make biological manufacturing programmable in a way it had never been before. Before recombinant insulin, diabetics depended on insulin extracted from the pancreases of slaughtered pigs and cattle, a supply constrained by livestock production and prone to triggering immune reactions in some patients; afterward, bacteria engineered to produce the human protein directly could, in principle, be scaled to whatever demand required. The same logic extended well beyond medicine, into cheese-making enzymes, agricultural traits and the broader biotechnology industry that grew up around companies like Genentech, founded specifically to commercialise techniques that, only a few years earlier, had existed only as an academic demonstration.
A decade from lab bench to industry
This is worth the time for how quickly and cleanly a laboratory technique turned into an industry, a licensed drug and a self-imposed regulatory framework, all within about a decade of the original 1973 demonstration. It rewards attention to the sequence of events rather than just the mechanism: the experiment, the patent filing a year later, the safety conference two years after that, and the first approved product roughly five years on, since that pacing is itself part of what makes the story instructive about how a genuinely new biological capability gets absorbed into medicine and industry. Readers should not expect deep technical detail on later gene-editing methods, which this material treats as outside its scope; what it offers instead is the origin point those later methods built on, told with reasonable completeness.